Comparative efficacy of bromocriptine, cabergoline and thyroxine in inducing oestrus in bitches.
Forty bitches in anoestrus for more than six months from the last heat, with a serum progesterone level less than 1 ng/ml were subjected to oestrus induction trials using anti-prolactin drugs and levothyroxine, once daily orally for 20 consecutive days. The mean serum progesterone level among them was found to be 0.57 +/- 0.03 ng/ml. Out of 10 animals treated in each group, five (50%) in Group I (bromocriptine @ 50 microg/kg body weight), nine (90%) in Group II (cabergoline @ 5 microg/kg body weight), eight (80%) in Group III (thyroxine @10 microg/kg body weight) and seven (70%) in Group IV (thyroxine @ 5 microg/kg body weight) responded by evincing proestrual bleeding. The mean (+/-SEM) time taken from initiation of treatment to onset of proestrual bleeding in Groups I, II, III and IV was 28 +/- 3.39, 13.44 +/- 3.12 (P < 0.05), 24.50 +/- 3.18 and 33 +/- 2.21 days respectively. The mean (+/-SEM) duration of proestrus and oestrus in the treatment groups was 9.80 +/- 0.86, 10.11 +/- 0.68, 11.25 +/- 0.88 and 10.71 +/- 0.68 days and 7.60 +/- 0.24, 8 +/- 0.29, 8.5 +/- 0.63 and 7.85 +/- 0.46 days respectively. The conception rate in relation to the number of animals responding to oestrus induction in the treatment groups was 80%, 78%, 63% and 57%, respectively. The mean (+/-SEM) gestation length calculated from the last breeding date and litter size in the treatment groups varied from 60.50 +/- 1.55 to 64.00 +/- 0.82 days and 5.14 +/- 0.34 to 6.40 +/- 0.40 respectively.
Ajitkumar
G
G
Department of Animal Reproduction, Gynaecology and Obstetrics, College of Veterinary and Animal Sciences, Kerala Agricultural University, Mannuthy, Thrissur, Kerala, India. ajitvet@yahoo.co.in
Sreekumaran
T
T
Praseeda
R
R
Mercy
K A
KA
Ghosh
K N Aravinda
KN
D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology*; D000077465:Cabergoline; D004285:Dogs; D004873:Ergolines / Q000493:pharmacokinetics*; D030762:Estrous Cycle / Q000187:drug effects*; D005260:Female; D005306:Fertilization / Q000187:drug effects*; D006727:Hormone Antagonists / Q000494:pharmacology; D008098:Litter Size / Q000187:drug effects*; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013974:Thyroxine / Q000494:pharmacology*
D004873:Ergolines; D006727:Hormone Antagonists; D001971:Bromocriptine; D011374:Progesterone; D011388:Prolactin; D000077465:Cabergoline; D013974:Thyroxine